Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
←Back to story

Sellas' experimental blood cancer immunotherapy reduced risk of death in clinical trial

STAT NewsView source article

Part of story

Sellas cancer vaccine significantly extends survival in AML trial

Sellas Life Sciences reported its experimental vaccine for acute myeloid leukemia significantly reduced risk of death in a late-stage clinical trial, sending shares to a record single-day surge. The unexpected positive result offers new hope for a difficult-to-treat blood cancer.

Nov 17, 2026·2 sourcesDrug Policy, Pricing & ApprovalCancer immunotherapyHematology & Blood CancersClinical trialsClinical trial endpointsFDA drug approval processCancer treatment breakthroughsCancer & Oncology
Sellas cancer vaccine significantly extends survival in AML trial
00

Other sources for this story

Reuters

Sellas vaccine extends survival in blood cancer trial, shares surge | Reuters